GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Gaush Meditech Ltd (HKSE:02407) » Definitions » Debt-to-EBITDA

Gaush Meditech (HKSE:02407) Debt-to-EBITDA : N/A (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Gaush Meditech Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Gaush Meditech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$588.0 Mil. Gaush Meditech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$138.7 Mil. Gaush Meditech's annualized EBITDA for the quarter that ended in Dec. 2023 was HK$0.0 Mil.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Gaush Meditech's Debt-to-EBITDA or its related term are showing as below:

HKSE:02407' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -4.54   Med: 3.29   Max: 171.01
Current: -3.5

During the past 5 years, the highest Debt-to-EBITDA Ratio of Gaush Meditech was 171.01. The lowest was -4.54. And the median was 3.29.

HKSE:02407's Debt-to-EBITDA is ranked worse than
100% of 434 companies
in the Medical Devices & Instruments industry
Industry Median: 1.21 vs HKSE:02407: -3.50

Gaush Meditech Debt-to-EBITDA Historical Data

The historical data trend for Gaush Meditech's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gaush Meditech Debt-to-EBITDA Chart

Gaush Meditech Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
3.29 6.57 171.01 -4.54 1.78

Gaush Meditech Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial -6.66 23.08 -2.03 N/A N/A

Competitive Comparison of Gaush Meditech's Debt-to-EBITDA

For the Medical Devices subindustry, Gaush Meditech's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gaush Meditech's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Gaush Meditech's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Gaush Meditech's Debt-to-EBITDA falls into.



Gaush Meditech Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Gaush Meditech's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(587.999 + 138.662) / 409.41
=1.77

Gaush Meditech's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(587.999 + 138.662) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.


Gaush Meditech  (HKSE:02407) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Gaush Meditech Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Gaush Meditech's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Gaush Meditech (HKSE:02407) Business Description

Traded in Other Exchanges
N/A
Address
No.11 Dongzhimen South Avenue, Room 1901, Building A, Zhonghui Plaza, Dongcheng District, Beijing, CHN
Gaush Meditech Ltd is a provider of a broad spectrum of ophthalmic medical devices. The segments of the company include 1) Proprietary products segment develops and produces surgical equipment and related supporting software, intra-optical lens, ophthalmic disease diagnosis and treatment equipment and related supporting consumables independently; 2) Distribution products segment sells multi-function diagnostic equipment, ocular fundus diagnosis, surgical and treatment equipment and related supporting consumables produced by ophthalmic medical equipment manufacturers; 3) Technical services segment provides warranty services, maintenance services and after-sales services related consumables; and 4) Others segment.

Gaush Meditech (HKSE:02407) Headlines

No Headlines